⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of ADARx Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
ADARx Pharmaceuticals
↗San Diego, USA
ADARx Pharmaceuticals is a clinical-stage biotechnology company focused on developing next-generation RNA-targeting therapeutics. The company utilizes proprietary oligonucleotide technologies for RNA inhibition, degradation, and editing, alongside advanced delivery systems such as the PLR™ (Preeminent Liver RNA) platform and SPE™ (Sequence Specific Platform Enhancement) technology.
ADARx is dedicated to addressing unmet medical needs across various therapeutic areas, including genetic, cardiometabolic, complement-mediated, and central nervous system (CNS) diseases. The company is advancing a robust pipeline of both wholly-owned clinical-stage programs and collaborative research efforts.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series C
Investors:Blackrock, Bain Capital Life Sciences
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:siRNA, Oligonucleotide, RNA editing
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AbbVie (Collaboration and license option agreement for next-gen siRNA therapeutics in neuroscience, immunology, and oncology)
COMPETITION
Position:Emerging
Competitors:Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals
LEADERSHIP
Key Executives:
Zhen Li - CEO and Co-founder
LINKS
Website:adarx.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with ADARx Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.